Baxter International Inc. BAX today announced that the company has
submitted a biologics license application (BLA) to the United States (U.S.)
Food and Drug Administration (FDA) for approval of BAX 326, a recombinant
factor IX (rFIX) protein being investigated for the treatment and prophylaxis
of bleeding episodes for patients over 12 years of age with hemophilia B.
Hemophilia B, also known as Christmas disease, is the second most common
type of hemophilia and results from insufficient amounts of clotting factor
IX, a naturally occurring protein in blood that helps to control bleeding.^1
Approximately 25,000 people worldwide, including more than 4,000 in the U.S.,
have been diagnosed with hemophilia B.^2
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in